{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:26:11Z","timestamp":1776432371762,"version":"3.51.2"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.clinthera.2008.03.008","type":"journal-article","created":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T13:58:05Z","timestamp":1207835885000},"page":"443-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment"],"prefix":"10.1016","volume":"30","author":[{"given":"Anthony I.","family":"Sebba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.03.008_bib1","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","volume":"843","year":"1994","journal-title":"Report of a WHO Study Group. World Health Organ Tech Rep Ser."},{"key":"10.1016\/j.clinthera.2008.03.008_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14656566.1.2.225","article-title":"Bisphosphonates in osteoporosis: Recent clinical experience","volume":"1","author":"McClung","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2008.03.008_bib3","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"for the Fracture Intervention Trial Research Group; Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.03.008_bib4","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2008.03.008_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"for the Hip Intervention Program Study Group; Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.03.008_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group; Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2008.03.008_bib7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","article-title":"similar antifracture efficacy in North American and European women: New clinical findings from BONE","volume":"21","author":"Chesnut","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2008.03.008_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S8756-3282(01)00667-6","article-title":"Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis","volume":"30","author":"Delmas","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2008.03.008_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jocd.2006.05.002","article-title":"for the International Society for Clinical Densitometry: Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference","volume":"9","author":"Binkley","year":"2006","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.clinthera.2008.03.008_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1258\/136218004774202409","article-title":"Non-response to osteoporosis treatment","volume":"10","author":"Francis","year":"2004","journal-title":"J Br Menopause Soc."},{"key":"10.1016\/j.clinthera.2008.03.008_bib11","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/(SICI)1097-0258(19990830)18:16<2177::AID-SIM181>3.0.CO;2-1","article-title":"Kher U; The impact of measurement error on the comparison of two treatments using a responder analysis","volume":"18","author":"Oppenheimer","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.clinthera.2008.03.008_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JCD:4:2:105","article-title":"Importance of precision in bone density measurements","volume":"4","author":"Bonnick","year":"2001","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.clinthera.2008.03.008_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1385\/JCD:6:4:307","article-title":"Nonresponders to osteoporosis therapy","volume":"6","author":"Lewiecki","year":"2003","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.clinthera.2008.03.008_bib14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3949\/ccjm.72.11.1033","article-title":"What is a \u2018failure\u2019 of bisphosphonate therapy for osteoporosis?","volume":"72","author":"Carey","year":"2005","journal-title":"Cleve Clin J Med."},{"key":"10.1016\/j.clinthera.2008.03.008_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jbspin.2004.07.003","article-title":"for the Comite Scientifique du GRIO; Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis","volume":"72","author":"Roux","year":"2005","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.clinthera.2008.03.008_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/BF02938621","article-title":"Monitoring osteoporosis therapies","volume":"5","author":"Miller","year":"2007","journal-title":"Curr Osteoporos Rep."},{"key":"10.1016\/j.clinthera.2008.03.008_bib17","first-page":"654","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in post-menopausal osteoporosis: 2 Year results from the MOBILE study [published correction appears in Ann Rheum Dis","volume":"65","author":"Reginster","year":"2006","journal-title":"2008;67:280]. Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2008.03.008_bib18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00198-004-1770-7","article-title":"Cummings SR; Risk of fracture among women who lose bone density during treatment with alendronate","volume":"16","author":"Chapurlat","year":"2005","journal-title":"The Fracture Intervention Trial. Osteoporos Int"},{"key":"10.1016\/j.clinthera.2008.03.008_bib19","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"for the Fracture Intervention Trial Research Group: Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2008.03.008_bib20","first-page":"2031","article-title":"for the Actonel Comparison Trial Investigators","volume":"20","author":"Sebba","year":"2004","journal-title":"Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis [published correction appears in Curr Med Res Opin. 2005;21:325]. Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2008.03.008_bib21","first-page":"2631","article-title":"Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years [published correction appears in J Clin Endocrinol Metab","volume":"91","author":"Bonnick","year":"2006","journal-title":"2007;92:3032]. J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2008.03.008_bib22","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2008.03.008_bib23","series-title":"Poster presented at: International Society for Clinical Densitometry 2006 Annual Meeting","article-title":"Increases in bone mineral density with once-monthly ibandronate: A post hoc responder rate analysis of the MOBILE study","author":"Hochberg","year":"2006"},{"key":"10.1016\/j.clinthera.2008.03.008_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk","volume":"7","author":"Watts","year":"2004","journal-title":"J Clin Densitom"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.03.008_bib25","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.bone.2006.01.159","article-title":"Risedronate demonstrates fracture efficacy in postmenopausal women whether there is a BMD gain or loss during treatment","volume":"38","author":"Watts","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2008.03.008_bib26","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1359\/JBMR.050814","article-title":"Felsenberg D; Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD","volume":"20","author":"Watts","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2008.03.008_bib27","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group; Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2008.03.008_bib28","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2008.03.008_bib29","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/sim.787","article-title":"Cummings SR; Estimating probability of nonresponse to treatment using mixture distributions","volume":"20","author":"Pavlic","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.clinthera.2008.03.008_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med."},{"key":"10.1016\/j.clinthera.2008.03.008_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2008.03.008_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.rhu.0000208612.33819.8c","article-title":"Important determinants of bone strength: Beyond bone mineral density","volume":"12","author":"Friedman","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2008.03.008_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.0954-6820.2003.01258.x","article-title":"Preventing osteoporotic fractures with antiresorptive therapy: Implications of microarchitectural changes","volume":"255","author":"Boonen","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2008.03.008_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-003-1530-0","article-title":"Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: Results from the BONE study","volume":"15","author":"Recker","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2008.03.008_bib35","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"and vertebral fracture in alendronatetreated women: The Fracture Intervention Trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2008.03.008_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2008.03.008_bib37","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s001980070002","article-title":"for the Committee of Scientific Advisors, International Osteoporosis Foundation; The use of biochemical markers of bone turnover in osteoporosis","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2008.03.008_bib38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0889-8529(05)70007-4","article-title":"Delmas PD; Biochemical markers of bone turnover","volume":"27","author":"Garnero","year":"1998","journal-title":"Applications for osteoporosis. Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.clinthera.2008.03.008_bib39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1365-2125.1999.00035.x","article-title":"The effect of dosing regimen on the pharmacokinetics of risedronate","volume":"48","author":"Mitchell","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2008.03.008_bib40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies of the oral bioavailability of alendronate","volume":"58","author":"Gertz","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.03.008_bib41","series-title":"Fosamax (alendronate sodium) [prescribing information].","year":"2007"},{"key":"10.1016\/j.clinthera.2008.03.008_bib42","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808001215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808001215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:47:47Z","timestamp":1758962867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808001215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0149291808001215"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.03.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}